Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ACTRN12626000694314) titled 'A Phase 1 Safety Study of ARG-397 in Healthy Adult Participants' on June 11.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety
Primary Sponsor: Arguello Biosciences, Inc.
Condition:
Thromboembolic disorders
Thromboembolic disorders
Blood - Clotting disorders
Intervention:
There are six dose cohorts planned for this study. Cohorts 1-4 and 6 will receive single subcutaneous (SC) injections of ARG-397. Cohort 5 (optional) will evaluate a single planned intravenous (IV) dose of ARG...